Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

SAB Biotherapeutics Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $1.27M Down From $3.59M YoY

Author: Benzinga Newsdesk | November 14, 2023 08:21am
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 37.5 percent increase over losses of $(0.16) per share from the same period last year. The company reported $1.27 million in sales this quarter. This is a 64.71 percent decrease over sales of $3.59 million the same period last year.

Posted In: SABS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist